How medically supervised weight management works, who it's suitable for and why clinical oversight matters.
Weight loss isn't always as simple as 'eat less, move more'. For many people, stubborn weight gain is linked to metabolic imbalances, insulin resistance and hormone regulation. Our medically supervised weight-management programme offers prescription support alongside personalised clinical guidance.
Mounjaro (tirzepatide) is a once-weekly injectable approved in the UK for weight management — for people with a BMI of 30 or above, or 27 or above with weight-related health issues. It acts on two appetite-regulating hormones, GLP-1 and GIP, which influence appetite, insulin sensitivity and fat metabolism.
It works by reducing appetite and cravings, slowing stomach emptying to prolong fullness, and improving the body's insulin response — leading to a sustainable reduction in calorie intake without extreme dieting. In clinical trials, patients achieved significant body-weight reductions over the course of treatment.
The programme is suited to people who struggle with appetite control or insulin resistance, who have plateaued despite diet and exercise, or who want a medically supervised, non-surgical solution. Clients often report added benefits such as improved energy, mood and control over emotional eating.
Side effects are mostly mild and temporary, such as nausea or bloating early on, with rarer concerns screened for in advance. Every client undergoes a full consultation and eligibility check, with regular reviews, nutritional and lifestyle support, and optional skin-tightening treatments to address any post-weight-loss laxity.
Mounjaro is a prescription-only medicine and is not suitable for everyone, including those who are pregnant or breastfeeding. A medical professional should always be consulted before starting any new medication.
Interested in a treatment?
Book a consultation with Dr Alexa in Mayfair, or send us a message with any questions.